Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension

被引:18
|
作者
Charalampopoulos, Athanasios [1 ]
Gibbs, J. Simon R. [1 ,2 ]
Davies, Rachel J. [1 ]
Gin-Sing, Wendy [1 ]
Murphy, Kevin [3 ]
Sheares, Karen K. [4 ]
Pepke-Zaba, Joanna [4 ]
Jenkins, David P. [5 ]
Howard, Luke S. [1 ,2 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Natl Pulm Hypertens Serv, London, England
[2] Imperial Coll London, Natl Heart & Lung Inst, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Resp Med, London, England
[4] Papworth Hosp, Pulm Dis Unit, Cambridge, England
[5] Papworth Hosp, Dept Cardiothorac Surg, Cambridge, England
关键词
chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension drug therapy; cardiopulmonary exercise testing; ARTERIAL-HYPERTENSION; THROMBOENDARTERECTOMY; BOSENTAN;
D O I
10.1152/japplphysiol.00087.2016
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
We tested the hypothesis that patients with chronic thromboembolic pulmonary hypertension (CTEPH) that was deemed to be inoperable were more likely to respond to drugs for treating pulmonary arterial hypertension (PAH) by using cardiopulmonary exercise (CPX) testing than those with CTEPH that was deemed to be operable. We analyzed CPX testing data of all patients with CTEPH who were treated with PAH drugs and had undergone CPX testing before and after treatment at a single pulmonary hypertension center between February 2009 and March 2013. Suitability for pulmonary endarterectomy (PEA) was decided by experts in PEA who were associated with a treatment center. The group with inoperable CTEPH included 16 patients, the operable group included 26 patients. There were no differences in demographics and baseline hemodynamic data between the groups. Unlike patients in the operable group, after drug treatment patients with inoperable CTEPH had a significantly higher peak (V)overdot(O2) (P < 0.001), work load (P = 0.002), and oxygen pulse (P < 0.001). In terms of gas exchange, there was an overall net trend toward improved (V)overdot(E)/(V)overdot(CO2) in the group with inoperable CTEPH, with an increased Pa-CO2 (P = 0.01), suggesting reduced hyperventilation. No changes were observed in patients with operable CTEPH. In conclusion, treatment with PAH drug therapy reveals important pathophysiological differences between inoperable and operable CTEPH, with significant pulmonary vascular and cardiac responses in inoperable disease. Drug effects on exercise function observed in inoperable CTEPH cannot be translated to all forms of CTEPH.
引用
收藏
页码:623 / 628
页数:6
相关论文
共 50 条
  • [31] Chronic thromboembolic pulmonary hypertension
    Fedullo, PF
    Auger, WR
    Channick, RN
    Kerr, KM
    Rubin, LJ
    CLINICS IN CHEST MEDICINE, 2001, 22 (03) : 561 - +
  • [32] Chronic thromboembolic pulmonary hypertension
    Auger, WR
    Kerr, KM
    Kim, NHS
    Ben-Yehuda, O
    Knowlton, KU
    Fedullo, PF
    CARDIOLOGY CLINICS, 2004, 22 (03) : 453 - +
  • [33] Prevalence of potential drug-drug interactions with disease-specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
    Norell, Puck N.
    Ivarsson, Bodil
    Selin, Maria
    Kjellstrom, Barbro
    PULMONARY CIRCULATION, 2022, 12 (03)
  • [34] Chronic thromboembolic pulmonary hypertension
    Guth, Stefan
    Wilkens, Heinrike
    Halank, Michael
    Held, Matthias
    Hobohm, Lukas
    Konstantinides, Stavros
    Omlor, Albert
    Seyfarth, Hans-Juergen
    Schaefers, Hans-Joachim
    Mayer, Eckhard
    Wiedenroth, Christoph B.
    PNEUMOLOGIE, 2023, 77 (11): : 937 - 946
  • [35] Chronic thromboembolic pulmonary hypertension
    Hoeper, Marius M.
    Madani, Michael M.
    Nakanishi, Norifumi
    Meyer, Bernhard
    Cebotari, Serghei
    Rubin, Lewis J.
    LANCET RESPIRATORY MEDICINE, 2014, 2 (07): : 573 - 582
  • [36] Chronic Thromboembolic Pulmonary Hypertension
    Teerapuncharoen, Krittika
    Bag, Remzi
    LUNG, 2022, 200 (03) : 283 - 299
  • [37] Chronic thromboembolic pulmonary hypertension
    B. E. Schölzel
    R. J. Snijder
    J. J. Mager
    H W. van Es
    H. W. M. Plokker
    H. J. Reesink
    W. J. Morshuis
    M. C. Post
    Netherlands Heart Journal, 2014, 22 : 533 - 541
  • [38] Chronic thromboembolic pulmonary hypertension
    Dartevelle, P
    Fadel, E
    Mussot, S
    Chapelier, A
    Hervé, P
    de Perrot, M
    Cerrina, J
    Ladurie, FL
    Lehouerou, D
    Humbert, M
    Sitbon, O
    Simonneau, G
    EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) : 637 - 648
  • [39] Chronic thromboembolic pulmonary hypertension
    Scholzel, B. E.
    Snijder, R. J.
    Mager, J. J.
    van Es, Hw.
    Plokker, H. W. M.
    Reesink, H. J.
    Morshuis, W. J.
    Post, M. C.
    NETHERLANDS HEART JOURNAL, 2014, 22 (12) : 533 - 541
  • [40] Chronic Thromboembolic Pulmonary Hypertension
    Olsson, Karen M.
    Meyer, Bernhard
    Hinrichs, Jan
    Vogel-Claussen, Jens
    Hoeper, Marius M.
    Cebotari, Serghei
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2014, 111 (50): : 856 - 862